Physician profile
Michael J Hagg
NPI 1477518991
$8,335.66
in general payments reported to CMS, 2019-2025
26 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,048 · 2020: $1,025 · 2021: $592 · 2022: $391 · 2023: $767 · 2024: $1,321 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,280.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $3,088.63 | 2019-2025 | Xtandi |
| Dendreon Pharmaceuticals LLC | $1,037.29 | 2019-2025 | Provenge |
| Neotract INC. | $840.58 | 2020 | |
| Janssen Biotech, INC. | $814.72 | 2019-2025 | Erleada, Akeega |
| Cook Medical LLC | $408.38 | 2020-2024 | Litho 150, Zenith Spiral-Z, Cook |
| Bayer Healthcare Pharmaceuticals INC. | $385.90 | 2019-2025 | |
| Procept Biorobotics Corporation | $245.48 | 2024-2025 | Aquabeam System |
| Abbvie INC. | $188.43 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $187.70 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $184.13 | 2024-2025 | |
| Olympus America INC. | $130.60 | 2021-2025 | Itind System |
| Janssen Scientific Affairs, LLC | $124.16 | 2023 | |
| Immunitybio, INC. | $118.90 | 2025 | |
| Medtronic, INC. | $114.53 | 2022-2023 | Interstim |
| Axonics, INC. | $90.66 | 2022-2024 | Axonics |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $82.78 | 2019-2025 | Axonics |
| Tolmar Pharmaceuticals, INC. | $52.80 | 2019 | |
| Pfizer INC. | $32.50 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $32.20 | 2024 | Orgovyx |
| Smith+Nephew, INC. | $32.09 | 2025 | Stravix, Stravix Pl |
| Progenics Pharmaceuticals, INC. | $29.80 | 2025 | |
| Profound Medical Corp. | $28.01 | 2025 | Tulsa-Pro |
| Tolmar, INC. | $27.63 | 2023 | |
| Urogen Pharma, INC. | $24.85 | 2023 | Jelmyto |
| Myriad Genetic Laboratories, INC. | $17.19 | 2022 | |
| Verity Pharmaceuticals INC. | $15.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hagg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.